Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer von Solomon, Benjamin J, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Tang, Yiyun, Wilner, Keith D, Blackhall, Fiona, Mok, Tony S

Volltext

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer von Solomon, Benjamin J, Mok, Tony, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Tursi, Jennifer, Blackhall, Fiona

Volltext

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration von Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.

Volltext

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer von Shaw, Alice T, Ou, Sai-Hong I, Bang, Yung-Jue, Camidge, D. Ross, Solomon, Benjamin J, Salgia, Ravi, Riely, Gregory J, Varella-Garcia, Marileila, Shapiro, Geoffrey I, Costa, Daniel B, Doebele, Robert C, Le, Long Phi, Zheng, Zongli, Tan, Weiwei, Stephenson, Patricia, Shreeve, S. Martin, Tye, Lesley M, Christensen, James G, Wilner, Keith D, Clark, Jeffrey W, Iafrate, A. John

Volltext

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib von Costa, Daniel B, Kobayashi, Susumu, Pandya, Shuchi S, Yeo, Wee-Lee, Shen, Zhongzhou, Tan, Weiwei, Wilner, Keith D

Volltext

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers von BERGETHON, Kristin, SHAW, Alice T, MARK, Eugene J, BATTEN, Julie M, HAIQUAN CHEN, WILNER, Keith D, KWAK, Eunice L, CLARK, Jeffrey W, CARBONE, David P, HONGBIN JI, ENGELMAN, Jeffrey A, MINO-KENUDSON, Mari, IGNATIUS OU, Sai-Hong, PAO, William, IAFRATE, A. John, KATAYAMA, Ryohei, LOVLY, Christine M, MCDONALD, Nerina T, MASSION, Pierre P, SIWAK-TAPP, Christina, GONZALEZ, Adriana, RONG FANG

Volltext

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer von Wu, Yi-Long, Yang, James Chih-Hsin, Kim, Dong-Wan, Lu, Shun, Zhou, Jianying, Seto, Takashi, Yang, Jin-Ji, Yamamoto, Noboru, Ahn, Myung-Ju, Takahashi, Toshiaki, Yamanaka, Takeharu, Kemner, Allison, Roychowdhury, Debasish, Paolini, Jolanda, Usari, Tiziana, Wilner, Keith D, Goto, Koichi

Volltext

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases von Costa, Daniel B, Shaw, Alice T, Ou, Sai-Hong I, Solomon, Benjamin J, Riely, Gregory J, Ahn, Myung-Ju, Zhou, Caicun, Shreeve, S Martin, Selaru, Paulina, Polli, Anna, Schnell, Patrick, Wilner, Keith D, Wiltshire, Robin, Camidge, D Ross, Crinò, Lucio

Volltext

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014 von Solomon, Benjamin J, Cappuzzo, Federico, Felip, Enriqueta, Blackhall, Fiona H, Costa, Daniel B, Kim, Dong-Wan, Nakagawa, Kazuhiko, Wu, Yi-Long, Mekhail, Tarek, Paolini, Jolanda, Tursi, Jennifer, Usari, Tiziana, Wilner, Keith D, Selaru, Paulina, Mok, Tony S K

Volltext

MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib von LENNERZ, Jochen K, KWAK, Eunice L, SALGIA, Ravi, BANG, Yung-Jue, CLARK, Jeffrey W, SOLOMON, Benjamin J, JOHN IAFRATE, A, ACKERMAN, Allison, MICHAEL, Michael, FOX, Stephen B, BERGETHON, Kristin, LAUWERS, Gregory Y, CHRISTENSEN, James G, WILNER, Keith D, HABER, Daniel A

Volltext

Crizotinib in Patients With MET-Amplified NSCLC von Camidge, D. Ross, Otterson, Gregory A., Clark, Jeffrey W., Ignatius Ou, Sai-Hong, Weiss, Jared, Ades, Steven, Shapiro, Geoffrey I., Socinski, Mark A., Murphy, Danielle A., Conte, Umberto, Tang, Yiyun, Wang, Sherry C., Wilner, Keith D., Villaruz, Liza C.

Volltext

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating... von Mok, Tony S., Cheng, Ying, Zhou, Xiangdong, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Niho, Seiji, Chawla, Alka, Rosell, Rafael, Corral, Jesus, Migliorino, Maria Rita, Pluzanski, Adam, Noonan, Kay, Tang, Yiyun, Pastel, Malaika, Wilner, Keith D., Wu, Yi-Long

Volltext

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer von Shaw, Alice T, Kim, Dong-Wan, Nakagawa, Kazuhiko, Seto, Takashi, Crinó, Lucio, Ahn, Myung-Ju, De Pas, Tommaso, Besse, Benjamin, Solomon, Benjamin J, Blackhall, Fiona, Wu, Yi-Long, Thomas, Michael, O'Byrne, Kenneth J, Moro-Sibilot, Denis, Camidge, D. Ross, Mok, Tony, Hirsh, Vera, Riely, Gregory J, Iyer, Shrividya, Tassell, Vanessa, Polli, Anna, Wilner, Keith D, Jänne, Pasi A

Volltext

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer von Wu, Yi-Long, Lu, Shun, Lu, You, Zhou, Jianying, Shi, Yuan-kai, Sriuranpong, Virote, Ho, James C.M., Ong, Choo Khoon, Tsai, Chun-Ming, Chung, Chin-Hee, Wilner, Keith D., Tang, Yiyun, Masters, Elizabeth T., Selaru, Paulina, Mok, Tony S.

Volltext

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer von FLAHERTY, Keith T, LORUSSO, Patricia M, DEMICHELE, Angela, ABRAMSON, Vandana G, COURTNEY, Rachel, RANDOLPH, Sophia S, SHAIK, M. Naveed, WILNER, Keith D, O'DWYER, Peter J, SCHWARTZ, Gary K

Volltext

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study von Mossé, Yael P, Dr, Lim, Megan S, MD, Voss, Stephan D, MD, Wilner, Keith, PhD, Ruffner, Katherine, MD, Laliberte, Julie, Rolland, Delphine, Balis, Frank M, Prof, Maris, John M, Prof, Weigel, Brenda J, MD, Ingle, Ashish M, MS, Ahern, Charlotte, PhD, Adamson, Peter C, Prof, Blaney, Susan M, Prof

Volltext

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group von Magnuson, Allison, Bruinooge, Suanna S, Singh, Harpreet, Wilner, Keith D, Jalal, Shadia, Lichtman, Stuart M, Kluetz, Paul G, Lyman, Gary H, Klepin, Heidi D, Fleury, Mark E, Hirsch, Brad, Melemed, Allen, Arnaldez, Fernanda I, Basu Roy, Upal, Schenkel, Caroline, Sherwood, Shimere, Garrett-Mayer, Elizabeth

Volltext

Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study von Camidge, D Ross, Dr, Bang, Yung-Jue, Prof, Kwak, Eunice L, MD, Iafrate, A John, MD, Varella-Garcia, Marileila, Prof, Fox, Stephen B, Prof, Riely, Gregory J, MD, Solomon, Benjamin, MBBS, Ou, Sai-Hong I, MD, Kim, Dong-Wan, Prof, Salgia, Ravi, Prof, Fidias, Panagiotis, MD, Engelman, Jeffrey A, MD, Gandhi, Leena, MD, Jänne, Pasi A, MD, Costa, Daniel B, MD, Shapiro, Geoffrey I, MD, LoRusso, Patricia, DO, Ruffner, Katherine, MD, Stephenson, Patricia, ScD, Tang, Yiyun, PhD, Wilner, Keith, PhD, Clark, Jeffrey W, MD, Shaw, Alice T, MD

Volltext

Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor von Butrynski, James E, D'Adamo, David R, Hornick, Jason L, Dal Cin, Paola, Antonescu, Cristina R, Jhanwar, Suresh C, Ladanyi, Marc, Capelletti, Marzia, Rodig, Scott J, Ramaiya, Nikhil, Kwak, Eunice L, Clark, Jeffrey W, Wilner, Keith D, Christensen, James G, Jänne, Pasi A, Maki, Robert G, Demetri, George D, Shapiro, Geoffrey I

Volltext

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 von Awad, Mark M, Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D, Timofeevski, Sergei, Wilner, Keith D, Lockerman, Elizabeth L, Khan, Tahsin M, Mahmood, Sidra, Gainor, Justin F, Digumarthy, Subba R, Stone, James R, Mino-Kenudson, Mari, Christensen, James G, Iafrate, A. John, Engelman, Jeffrey A, Shaw, Alice T

Volltext